You are here

P&T News

April 29

Combo treatment with lenalidomide and dexamethasone extends progression-free survival
Topoisomerase 1 inhibitors may blunt inflammatory storms
First authorized test from commercial lab in U.S.

April 28

Medicare EHR incentive system will be phased out
Guidance emphasizes individualized treatment

April 27

Hospitals, insurers, and businesses prod drug-makers
Product overcomes patent-infringement lawsuit

April 26

Approval decision expected by May 26
Treatment demonstrates superior improvement in lung function versus mono-components and placebo
Therapy improves overall survival, progression-free survival, and objective response rate in phase 3 trial
Nonprofit group issues safety score update